Celldex Therapeutics Inc [CLDX] stock is trading at $20.49, down -2.01%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CLDX shares have gain 4.43% over the last week, with a monthly amount glided 8.18%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Celldex Therapeutics Inc [NASDAQ: CLDX] stock has seen the most recent analyst activity on April 28, 2025, when Canaccord Genuity initiated its Buy rating and assigned the stock a price target of $64. Previously, Morgan Stanley started tracking the stock with Overweight rating on March 20, 2025, and set its price target to $46. On February 13, 2025, UBS initiated with a Buy rating and assigned a price target of $44 on the stock. Citigroup started tracking the stock assigning a Buy rating and suggested a price target of $70 on October 07, 2024. Goldman initiated its recommendation with a Neutral and recommended $45 as its price target on September 30, 2024. Wolfe Research downgraded its rating to Peer Perform for this stock on September 27, 2024. In a note dated June 18, 2024, Stifel initiated an Buy rating and provided a target price of $58 on this stock.
Celldex Therapeutics Inc [CLDX] stock has fluctuated between $14.40 and $47.00 over the past year. Currently, Wall Street analysts expect the stock to reach $46 within the next 12 months. Celldex Therapeutics Inc [NASDAQ: CLDX] shares were valued at $20.49 at the most recent close of the market. An investor can expect a potential return of 124.5% based on the average CLDX price forecast.
Analyzing the CLDX fundamentals
Celldex Therapeutics Inc [NASDAQ:CLDX] reported sales of 7.56M for the trailing twelve months, which represents a growth of 345.51%. Gross Profit Margin for this corporation currently stands at 0.69% with Operating Profit Margin at -20.44%, Pretax Profit Margin comes in at -23.66%, and Net Profit Margin reading is -23.66%. To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -0.23 and Total Capital is -0.22. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Celldex Therapeutics Inc’s Current Ratio is 21.67. As well, the Quick Ratio is 21.67, while the Cash Ratio is 0.54. Considering the valuation of this stock, the price to sales ratio is 179.95, the price to book ratio is 1.93.
Transactions by insiders
Recent insider trading involved Marucci Anthony S, PRESIDENT & CEO, that happened on Nov 11 ’24 when 11500.0 shares were purchased. SVP AND CFO, Martin Samuel Bates completed a deal on Jun 14 ’24 to sell 17172.0 shares. Meanwhile, SR. VP & CPDO Crowley Elizabeth sold 30000.0 shares on Jun 14 ’24.
